P2RY12

(redirected from P2Y)

P2RY12

A gene on chromosome 3q24-q25 that encodes a G protein-coupled receptor for various drugs as well adenosine and uridine nucleotides.
Mentioned in ?
References in periodicals archive ?
PKC- and ERK-dependent activation of I kappa B kinase by lipopolysaccharide in macrophages: enhancement by P2Y receptor-mediated CaMK activation.
Substances known to specifically block the platelet's P2Y 12 receptor include the thienopyridine class of drugs, including clopidogrel, prasugrel, ticagrelor, and ticlopidine.
Effects of Elevated Fibrinogen, Factor VIII, and von Willebrand factor on the INNOVANCE[R] PFA P2Y cartridge
Key classes of mechanism of action include endothelin receptor antagonists, platelet aggregation inhibitors, phosphodiesterase inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, P2Y 12 receptor inhibitors, PDE5 inhibitors, prostacyclin (PGI2) agonists, nitric oxide synthetase inhibitors.
The effect of ADP on platelets is mediated by two P2Y receptors, designated P2Y1 and P2Y12.
A loading dose of a P2Y 12 receptor inhibitor should be given as early as possible or at time of primary PCI to patients with STEMI.
Purinergic receptors are subdivided into metabotropic P2Y receptors and ionotropic P2X receptors.
Current efforts are directed toward the possibilities of dual antiplatelet drug therapy; alternative P2Y 12 antagonists, such as prasugrel and ticagrelor; or the addition of antithrombotic drugs, such as dipyridamole or cilostazole.
Pre-defined cutoffs for clopidogrel-induced P2Y12 receptor blockade were: P2Y >106sec and VNP >20% inhibition.
2+] transients, likely mediated through agonist actions on P2Y purinergic nucleotide receptors expressed in IDCs (Idzko et al.
A loading dose of P2Y 12 receptor inhibitor therapy is recommended for UA/NSTEMI patients for whom PCI is planned.